Quantum BioPharma Targets MS Progression with Novel Demyelination Therapy in Phase 2 Push
Quantum BioPharma (NASDAQ:QNTM) is taking a meaningful step forward in its clinical ambitions, signing a binding letter of intent with Allucent to advance its lead multiple sclerosis candidate, Lucid-21-302 (Lucid-MS), into a Phase 2 trial. The agreement signals more than operational progress, it reflects a broader push to bring differentiated, next-generation therapies into a market that remains heavily underserved despite decades of innovation.